Display of pseudo-natural peptides and products

Hiroaki Suga

Department of Chemistry, Graduate School of Science, The University of Tokyo, Japan
hsuga@chem.s.u-tokyo.ac.jp

Lor Macrocyclic peptides possess a number of pharmacological characteristics distinct from other well-established therapeutic molecular classes, resulting in a versatile drug modality with a unique profile of advantages. Macrocyclic peptides are accessible by not only chemical synthesis but also ribosomal synthesis. Particularly, recent inventions of the genetic code reprogramming integrated with an in vitro display format, referred to as RaPID (Random non-standard Peptides Integrated Discovery) system, have enabled us to screen mass libraries (>1 trillion members) of non-standard peptides containing multiple non-proteinogenic amino acids, giving unique properties of peptides distinct from conventional peptides, e.g. greater proteolytic stability, higher affinity (low nM to sub nM dissociation constants similar to antibodies), and superior pharmacokinetics. The field is rapidly growing evidenced by increasing interests from industrial sectors, including small start-ups as well as mega-pharmas, toward drug development efforts on macrocyclic peptides, which has led to several *de novo* discovered peptides entering clinical trials. This lecture discusses the aforementioned screening technology, the RaPID system, and several showcases of therapeutic potentials of macrocyclic peptides. This lecture also discusses the most recent advance in the display of pseudo-natural products generated by thiopeptide post-translationally modifying enzymes.

[1]"Accurate Broadcasting of Substrate Fitness for Lactazole Biosynthetic Pathway from Reactivity-Profiling mRNA Display." A. Vinogradov; E. Nagai; J.S. Chang; K. Narumi; H. Onaka; Y. Goto; H. Suga*; **Journal of the American Chemical Society**, (2020)

[2]"Ribosomal Elongation of Aminobenzoic Acid Derivatives." T. Katoh; H. Suga*; **Journal of the American Chemical Society,** 142, 16518-16522 (2020)

[3]"GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf." Z. Zhang; R. Gao; Q. Hu; H. Peacock; D.M. Peacock; S. Dai; K.M. Shokat; H. Suga* ACS Cent. Sci., (2020)

[4]"Development of cyclic peptides with potent in vivo osteogenic activity through RaPID-based affinity maturation" N. K. Bashiruddin; M. Hayashi; M. Nagano; Y. Wu; Y. Matsunaga; J. Takagi; T. Nakashima; H. Suga*; **Proceedings of the National Academy of Sciences USA** 117 (49) 31070-31077 (2020)

[5]"Ribosomal synthesis and de novo discovery of bioactive foldamer peptides containing cyclic β-amino acids" T. Katoh; T. Sengoku; K. Hirata; K. Ogata; H. Suga*; **Nature Chemistry** 12, 1081-1088 (2020)

[6]"Promiscuous enzymes cooperate at the substrate level en route to lactazole A" A.A. Vinogradov; M. Shimomura; N. Kano; Y. Goto; H. Onaka, H. Suga*; **Journal of the American Chemical Society** 142, 13886-13897 (2020)

[7]"Introduction to Thiopeptides: Biological Activity, Biosynthesis, and Strategies for Functional Reprogramming" A.A. Vinogradov; H. Suga*; **Cell Chemical Biology**, Accepted article (2020)

[8]"Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy" D. Hanzawa; Y. Yin; Y. Murata; M. Matsuda; T. Okamoto; D. Tanaka, N. Terasaka; Jinxuan Zhao, M. Sakamoto; Y. Kakuchi; Y. Saito; T. Kotani; Y. Nishimura; A. Nakagawa; H. Suga*; T. Matozaki; **Cell Chemical Biology**, 27, 1181-1191 (2020)

[9]"Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor"K. Sakai; T. Passioura; H. Sato; K. Ito; H. Furuhashi; M. Umitsu; J. Takagi; Y. Kato; H. Mukai; S. Warashina; M. Zouda; Y. Watanabe; S. Yano; M. Shibata; H. Suga*; K. Matsumoto; **Nature Chemical Biology**, 15, 598-606 (2019)

[10]M. Nawatha; J.M. Rogers; S.M. Bonn; I. Livneh; B. Lemma; S.M. Mali; G.B. Vamisetti; H. Sun; B. Bercovich; Y. Huang; A. Ciechanover; D. Fushman; H. Suga*; A. Brik; "De novo macrocyclic peptides that specifically modulate Lys48-linked ubiquitin chains." **Nature Chemistry**, 11(7):644-652 (2019)